These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 29366679)

  • 21. Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease.
    Benoy V; Vanden Berghe P; Jarpe M; Van Damme P; Robberecht W; Van Den Bosch L
    Neurotherapeutics; 2017 Apr; 14(2):417-428. PubMed ID: 27957719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.
    Amengual JE; Johannet P; Lombardo M; Zullo K; Hoehn D; Bhagat G; Scotto L; Jirau-Serrano X; Radeski D; Heinen J; Jiang H; Cremers S; Zhang Y; Jones S; O'Connor OA
    Clin Cancer Res; 2015 Oct; 21(20):4663-75. PubMed ID: 26116270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease.
    Caballero-Camino FJ; Rivilla I; Herraez E; Briz O; Santos-Laso A; Izquierdo-Sanchez L; Lee-Law PY; Rodrigues PM; Munoz-Garrido P; Jin S; Peixoto E; Richard S; Gradilone SA; Perugorria MJ; Esteller M; Bujanda L; Marin JJG; Banales JM; Cossío FP
    Hepatology; 2021 Jan; 73(1):186-203. PubMed ID: 32145077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
    Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Santos-Laso A; Azkargorta M; Elortza F; Martinez-Chantar ML; Perugorria MJ; Aspichueta P; Marzioni M; LaRusso NF; Bujanda L; Drenth JPH; Banales JM
    J Hepatol; 2021 Feb; 74(2):394-406. PubMed ID: 32950589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.
    Zhang L; Liu C; Wu J; Tao JJ; Sui XL; Yao ZG; Xu YF; Huang L; Zhu H; Sheng SL; Qin C
    J Alzheimers Dis; 2014; 41(4):1193-1205. PubMed ID: 24844691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
    Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
    Apoptosis; 2017 Jun; 22(6):827-840. PubMed ID: 28315173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-β and EGFR signaling pathways in obstructive nephropathy.
    Chen X; Yu C; Hou X; Li J; Li T; Qiu A; Liu N; Zhuang S
    Am J Physiol Renal Physiol; 2020 Dec; 319(6):F1003-F1014. PubMed ID: 33103445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca
    Yanda MK; Liu Q; Cebotaru V; Guggino WB; Cebotaru L
    J Biol Chem; 2017 Oct; 292(43):17897-17908. PubMed ID: 28887310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.
    North BJ; Almeciga-Pinto I; Tamang D; Yang M; Jones SS; Quayle SN
    PLoS One; 2017; 12(3):e0173507. PubMed ID: 28264055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.
    Lee DH; Kim GW; Kwon SH
    Mol Carcinog; 2019 Jun; 58(6):944-956. PubMed ID: 30693983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.
    Urribarri AD; Munoz-Garrido P; Perugorria MJ; Erice O; Merino-Azpitarte M; Arbelaiz A; Lozano E; Hijona E; Jiménez-Agüero R; Fernandez-Barrena MG; Jimeno JP; Marzioni M; Marin JJ; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Banales JM
    Gut; 2014 Oct; 63(10):1658-67. PubMed ID: 24436140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.
    Huang P; Almeciga-Pinto I; Jarpe M; van Duzer JH; Mazitschek R; Yang M; Jones SS; Quayle SN
    Oncotarget; 2017 Jan; 8(2):2694-2707. PubMed ID: 27926524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective Effects of ACY-1215 Against Chemotherapy-Related Cognitive Impairment and Brain Damage in Mice.
    Wang D; Wang B; Liu Y; Dong X; Su Y; Li S
    Neurochem Res; 2019 Nov; 44(11):2460-2469. PubMed ID: 31571096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy.
    Wen Y; Ye S; Li Z; Zhang X; Liu C; Wu Y; Zheng R; Xu C; Tian J; Shu L; Yan Q; Ai F; Ma J
    Cancer Immunol Immunother; 2024 Jan; 73(1):7. PubMed ID: 38231305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
    Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
    J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability.
    Jochems J; Boulden J; Lee BG; Blendy JA; Jarpe M; Mazitschek R; Van Duzer JH; Jones S; Berton O
    Neuropsychopharmacology; 2014 Jan; 39(2):389-400. PubMed ID: 23954848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.
    Vekaria PH; Kumar A; Subramaniam D; Dunavin N; Vallurupalli A; Schoenen F; Ganguly S; Anant S; McGuirk JP; Jensen RA; Rao R
    Leukemia; 2019 Jul; 33(7):1675-1686. PubMed ID: 30664664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation.
    Tsuji G; Okiyama N; Villarroel VA; Katz SI
    J Allergy Clin Immunol; 2015 May; 135(5):1228-39. PubMed ID: 25458911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.